RxDoctor Payments Data

James Kempiners, MD

Otolaryngology · Fort Thomas, KYNPI 1598842213

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Optinose US, Inc. accounts for 67.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $5,147 and has fallen 96.3% since, to $193 in 2025. Among otolaryngology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,015in general payments, 2019–2025

Across 103 payments — averaging $68.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$5K
  • Stryker$765
  • Acclarent, Inc$632
  • Sanofi$170
  • Regeneron Healthcare Solutions, Inc.$134
  • Alk-abello, Inc$107
  • plus $486 from 16 others

What the payments were for

  • Consulting fees$3,00043%
  • Travel & lodging$1,17417%
  • Food & beverage$2,84040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,015 in reported general payments places this provider in the 90th percentile of 137 otolaryngology providers in Kentucky.

See all otolaryngology providers in Kentucky

Medicare billing

Part B allowed, 2024
$70,489
Medicare patients
258
Services billed
1,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$41,163
Epinephrine14$2,544
Fluticasone Propionate215$2,093
Azelastine Hcl89$1,486
Fluocinolone Acetonide Oil32$1,284
Ofloxacin24$791
Ipratropium Bromide31$587
Montelukast Sodium84$576
Cefdinir24$505
Mometasone Furoate18$421
Pantoprazole Sodium19$275
Levofloxacin11$66
Topiramate16$64
Diazepam12$51
Gabapentin11$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$14$2,54414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 137 otolaryngology providers in Kentucky.

Other otolaryngology in Fort Thomas

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →